References
- Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor expression. Cytokine. 2010;51: 178–83.
- Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.
- Gravallese EM, Darling JM, Ladd AL, Katz JN, Gfimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum. 1991;34:1076–84.
- Hasty KA, Reife RA, Kang AH, Stuart JM. The role of strom-elysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 1990;33:388–97.
- Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a pre-dictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852–8.
- Klimiuk PA, Sierakowski S, Chwiecko J. Serum interleukin 6 (IL-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn. 2003;109: 119–23.
- Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507–12.
- Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol. 2007;17:403–8.
- Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Ro-vensky J, Alecock E, et al. Effect of interleukin-6 receptor inhi-bition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987–97.
- Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multi-center double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33–43.
- Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of theinterleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.